Gyre Therapeutics, Inc. Repayments of Convertible Debt
Gyre Therapeutics, Inc. (GYRE) reported Repayments of Convertible Debt of $5.08 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-20.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2020-02-20
- Gyre Therapeutics, Inc. repayments of convertible debt for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- Gyre Therapeutics, Inc. repayments of convertible debt for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- Gyre Therapeutics, Inc. repayments of convertible debt for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- Gyre Therapeutics, Inc. repayments of convertible debt for the quarter ending 2018-03-31 was $5.08M, a 24.73% decline year-over-year.
- Gyre Therapeutics, Inc. repayments of convertible debt for fiscal 2018 was $5.08M, a 64.51% decline from fiscal 2017.
- Gyre Therapeutics, Inc. repayments of convertible debt for fiscal 2017 was $14.32M, a 0.15% decline from fiscal 2016.
- Gyre Therapeutics, Inc. repayments of convertible debt for fiscal 2016 was $14.34M, a 374.83% increase from fiscal 2015.
- Gyre Therapeutics, Inc. repayments of convertible debt for fiscal 2015 was $3.02M.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | $0.00 derived: sum of 2 quarters · filed 2020-02-20 | $0.00 derived: sum of 3 quarters · filed 2020-02-20 | $5.08M 10-K · filed 2020-02-20 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $5.08M 10-Q · filed 2019-11-07 | $5.49M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $5.08M 10-Q · filed 2019-08-01 | $5.49M derived: sum of 3 quarters · filed 2019-08-01 | $5.77M derived: sum of 4 quarters · filed 2019-08-01 |
| 2018-03-31 | $5.08M 10-Q · filed 2019-05-02 | $5.49M derived: sum of 2 quarters · filed 2019-05-02 | $5.77M derived: sum of 3 quarters · filed 2019-05-02 | $12.65M derived: sum of 4 quarters · filed 2019-05-02 |
| 2017-12-31 | $403.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $685.00K derived: sum of 2 quarters · filed 2019-03-08 | $7.57M derived: sum of 3 quarters · filed 2019-03-08 | $14.32M 10-K · filed 2019-03-08 |
| 2017-09-30 | $282.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $7.16M derived: sum of 2 quarters · filed 2018-11-01 | $13.91M 10-Q · filed 2018-11-01 | $24.18M derived: sum of 4 quarters · filed 2018-11-01 |
| 2017-06-30 | $6.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $13.63M 10-Q · filed 2018-08-02 | $23.90M derived: sum of 3 quarters · filed 2018-08-02 | $24.57M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-03-31 | $6.75M 10-Q · filed 2018-05-03 | $17.02M derived: sum of 2 quarters · filed 2018-05-03 | $17.69M derived: sum of 3 quarters · filed 2018-05-03 | $18.29M derived: sum of 4 quarters · filed 2018-05-03 |
| 2016-12-31 | $10.27M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | $10.94M derived: sum of 2 quarters · filed 2018-03-19 | $11.53M derived: sum of 3 quarters · filed 2018-03-19 | $14.34M 10-K · filed 2018-03-19 |
| 2016-09-30 | $676.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $1.27M derived: sum of 2 quarters · filed 2017-11-02 | $4.08M 10-Q · filed 2017-11-02 | $4.94M derived: sum of 4 quarters · filed 2017-11-02 |
| 2016-06-30 | $592.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $3.40M 10-Q · filed 2017-08-03 | $4.26M derived: sum of 3 quarters · filed 2017-08-03 | |
| 2016-03-31 | $2.81M 10-Q · filed 2017-05-11 | $3.67M derived: sum of 2 quarters · filed 2017-05-11 | ||
| 2015-12-31 | $863.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $3.02M 10-K · filed 2017-03-08 | ||
| 2015-09-30 | $2.16M 10-Q · filed 2016-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |